Hypertension has been strongly linked to a variety of lipoprotein metabolic abnormalities. Polymorphisms in the genes encoding the lipoproteins involved in metabolic abnormalities are the major target for evaluating the predisposition to the development of hypertension. In this study, two candidate genes including apolipoprotein E (ApoE) and low-density lipoprotein receptor (LDLR) were selected to examine their possible contribution to hypertension in a Chinese Han population.
Hypertension is a complex multifactorial and polygenic disorder that is thought to result from an interaction between an individual's genetic makeup and various environmental factors. 1 Given that hypertension is a major risk factor for cardiovascular diseases, stroke and end-stage renal disease and prevails globally, prevention of hypertension is an important public health goal. 2 One preventive approach is to identify disease-susceptibility genes that involve a specific physiological or cellular function.
There is growing awareness that patients with hypertension tend to have a high prevalence of associated dyslipidemias such as the elevated total cholesterol (TC) and triglycerides (TG), and reduced low-density lipoprotein cholesterol (LDLC). 3 However, the exact mechanism leading to these dyslipidemias remains unknown. It is reasonable to expect that multiple genetic and/or physiological safeguards have developed to maintain lipoprotein levels within a range of physiologically acceptable levels. To address this issue, we performed an association study for two lipoprotein-related gene polymorphisms and hypertension. Our aim was to evaluate the relationship of these polymorphisms with hypertension, as well as blood pressure and plasma lipoprotein profiles, both solely and combined in a Chinese population.
All subjects in this study were of Han Chinese currently residing in Shijiazhuang city. A total of 269 hypertensives (153 male subjects/116 female subjects) met the following criteria: (1) onset of hypertension before age 65 years; (2) systolic blood pressure (SBP)X140 mm Hg or diastolic BP (DBP)X90 mm Hg; (3) free of secondary causes of hypertension through extensive biochemical and clinical examination; (4) without pharmacological treatment for hypertension. The BP of all 236 normotensives (131 male subjects/105 female subjects) was below 140/90 mm Hg; all normotensives matched hypertensives for area, gender and age without familial hypertension history, hepatic disease, renal insufficiency and diabetes. This study was approved by the Ethics Committee of Chinese Academy of Medical Sciences/Peking Union Medical College and informed consent was obtained from each subject.
Blood samples were drawn for DNA extraction and biochemical examination. Genomic DNA was extracted from white blood cells. Plasma TC, TG and high-density lipoprotein cholestrol (HDLC) concentrations were determined enzymatically using commercially available kits and auto analyzer, and LDLC was estimated using Friedewald's formula.
Two common polymorphisms including ApoE e2/e3/e4 (rs7412/429358) and LDLR C1773T (rs688) were selected based on physiological, biochemical and genetic studies reported previously. They are involved in the regulation of lipoprotein metabolism. The amplification of ApoE e2/e3/e4 polymorphism was performed with the primers 5 0 -AAC AAC TGA CCC CGG TGG CG-3 0 (sense) and 5 0 -ATG GCG CTG AGG CCG CGC TC-3 0 (antisense). Polymerase chain reaction (PCR) reactions began with an initial denaturation at 941C (5 min), then 30 cycles of 941C (45 s), 651C (45 s) and 721C (45 s), followed by a final extension at 721C (5 min). PCR products were restricted with HhaI (Promega, Beijing, China), and separated on 8% polyacrylamide gels. The C1773T polymorphism of LDLR was genotyped according to the previous report. 4 Statistical calculations were performed using SAS 9.1.3 (Institute Inc., Cary, NC, USA). Hardy-Weinberg (H-W) equilibrium was tested using w 2 test. Comparisons among different means were calculated using ANOVA. The association between polymorphisms and hypertension was analysed by logistic regression; odds ratio (OR), and 95% confidence interval were calculated. Data were expressed as mean7s.d.; all P-values were two-sided; Po0.05 was considered statistically significant.
The genotype distributions for the polymorphisms analysed were shown in Table 1 and were in H-W equilibrium except for LDLR C1773T in hypertensives (P ¼ 0.0049). Both ApoE and LDLR genotype and allele distributions showed significances between the two groups (all Po0.001). The frequency of e2 allele was 33.3% in normotensives and 28.3% in hypertensives, whereas the frequency of e4 allele was 5.7% in normotensives but high up to 20.0% in hypertensives. The OR for the e4 allele was 4.14, with 95%CI from 2.66 to 6.44 (Po0.0001) (data not shown). The frequency of 1773T allele was 45.0% in hypertensives, which was significantly higher than in normotensives (28.2%); the OR for 1773T allele was 2.08, with 95%CI from 1.60 to 2.71 (Po0.0001) (data not shown).
To investigate the effects of ApoE genotypes on lipoprotein profiles, subjects with the ApoE2/4 genotype were excluded from the analysis, because of the opposite effects of these two alleles on lipoprotein metabolism. Compared with ApoE e3 allele, e4 allele carriers showed higher levels of TC and LDLC (all Po0.05). For C1773T, the TT homozygote carriers showed a higher TC and LDLC levels and a lower HDLC levels than CC homozygote carriers. The 1773T allele carriers showed higher diastolic BP than CC homozygote carriers. With respect to genotype combinations, the differences between E2/2 þ E2/3ÀCC and E3/4 þ E4/4ÀTT combinations in terms of plasma TC, LDLC and HDLC levels were significant (all Po0.05).
Since the presence of ApoE polymorphism was first described by Utermann et al., 5 some studies have suggested that ApoE was functional. Structural defects of ApoE might result in an impaired interaction of ApoE containing lipoproteins with its receptors and induce the development of atherogenic dyslipidaemias and premature cardiovascular diseases. 6 ApoE gene knockout mice showed hypertension and endothelial dysfunction, which suggested that ApoE might directly contribute to the endothelial function. 7 In our study, plasma TC and LDLC levels tended to be higher in subjects with e4 allele compared with e3 allele similar to a previous study. 8 One possible explanation is that e4 allele does not carry a supradyl group and therefore, e4 lipoproteins undergo oxidation and are cleared by scavenger receptors more easily than e3 lipoproteins. 9 Thus, we hypothesised that if ApoE involved, the e4 allele would be associated with hypertension in part via modulating lipoprotein levels.
With regard to LDLR, a recent paper on the maleassociated hypertension in LDLR-deficient mice suggested that LDLR was not only involved in lipid metabolism, but also in the unknown pathogenesis of hypertension. 10 Hegele et al. 11 estimated that variation in the LDLR gene accounted for about 2.5% of the variation in plasma LDLC levels. In this study, our data showed that in hypertensives, TT homozygote carriers conferred a higher diastolic BP, TC and LDLC levels and a lower HDLC levels than other carriers. We can speculate that C1773T variant correlated with diastolic hypertension via modulating circulating lipoproteins. As C1773T variant is per se silent at the amino-acid level, there must be another functional variant with or flanking the LDLR gene in linkage disequilibrium.
In this study, C1773T genotype distribution deviated from H-W equilibrium in hypertensives.
Deviations from H-W equilibrium, especially in affected individuals, can provide evidence for an association between the marker and disease susceptibility. 12 Given the validity of our study design, this is yet another indication that C1773T variant is a potentially genetic marker for hypertension.
In summary, our study demonstrated a strong correlation of ApoE and LDLR gene polymorphisms with hypertension and plasma lipoprotein levels in a Chinese population. Therefore, the polymorphisms studied may be potentially useful genetic markers for hypertension. Further research in different populations is required to elucidate the relationship between these polymorphisms and hypertension, and mechanisms of the ApoE and LDLR genes and hypertension. W Niu 1 , X Guo 2 , Y Su 2 and C Qiu
